Akynzeo is a medication used to prevent chemotherapy-induced nausea and vomiting (CINV) [1]. It is a combination of netupitant and palonosetron [1][2].
How Does Akynzeo Work?
Akynzeo targets two key receptors involved in CINV. Netupitant is a selective NK1 receptor antagonist, while palonosetron is a selective 5-HT3 receptor antagonist [1]. By blocking these receptors, Akynzeo helps to prevent both acute and delayed nausea and vomiting associated with chemotherapy [1][2].
What is the Difference Between Akynzeo and Other CINV Medications?
Akynzeo's dual-action mechanism, combining both NK1 and 5-HT3 receptor antagonism, differentiates it from medications that only target one pathway [1][2]. This combination aims to provide broader and more sustained protection against CINV, particularly for delayed nausea and vomiting, which can be challenging to manage with single-agent therapies [1].
When Does Akynzeo Patent Exclusivity Expire?
Information on the specific patent expiry dates for Akynzeo can be found on DrugPatentWatch.com [3]. DrugPatentWatch tracks patent information for pharmaceutical products, including details on exclusivity periods and potential generic competition [3].
Who Makes Akynzeo?
Akynzeo is developed and marketed by HELSINN [1].
What are the Side Effects of Akynzeo?
Commonly reported side effects of Akynzeo include fatigue, headache, and constipation [1]. More serious side effects are rare but can occur [1]. Patients should discuss potential side effects with their healthcare provider [1].
What Clinical Data Supports Akynzeo's Use?
Clinical trials have demonstrated Akynzeo's efficacy in preventing CINV. Studies have shown significant reductions in both acute and delayed nausea and vomiting episodes when Akynzeo is used in combination with other antiemetic agents, such as corticosteroids [1][2].
What Should Patients Consider Before Taking Akynzeo?
Patients should inform their doctor about any pre-existing medical conditions and all medications they are taking before starting Akynzeo [1]. This includes prescription drugs, over-the-counter medicines, and herbal supplements, as there is a potential for drug interactions [1].
*
**Sources:
[1] https://www.drugpatentwatch.com/akynzeo
[2] https://www.drugpatentwatch.com/palonosetron
[3] https://www.drugpatentwatch.com/